Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...
An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...
21 小时
Tribune Content Agency on MSNThe Medicine Cabinet: Ask the Harvard Experts: Why an aortic valve can narrow and impede ...Q: My doctor heard a new heart murmur and suspected I have a narrowed valve due to aortic stenosis. I feel fine. Why did this ...
2 天
News Medical on MSNNew drug ataciguat shows promise for managing aortic valve stenosisAortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.
Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.
2 天
Medpage Today on MSNAtaciguat's Headway in Aortic Stenosis; Baby Pacemakers; AI-ECG Tool for the ED?The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...
Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...
If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.
Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers at Mayo Clinic are exploring the use of a new drug called ...
Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers at Mayo Clinic are exploring the use of a new drug called ...
Sanofi's experimental drug ataciguat has shown promise in reducing the progression of aortic valve stenosis in clinical trials, potentially delaying the need for surgical valve replacement. With ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果